cLF36: A Camel Milk-Derived Peptide That Fights Bacteria, Viruses, and Cancer Cells
A chimeric peptide engineered from camel milk lactoferrin shows broad antimicrobial, antiviral, and anticancer activity while remaining non-toxic to normal cells and stable in blood serum.
Quick Facts
What This Study Found
Researchers developed cLF36, a chimeric 42-amino acid peptide combining the complete camel lactoferrampin sequence with a partial lactoferricin sequence. Testing across multiple platforms showed broad-spectrum antimicrobial activity against human, avian, and plant bacterial pathogens. The peptide also demonstrated antiviral effects against hepatitis C virus, influenza virus, and rotavirus in computational and in vitro studies.
Notably, cLF36 showed selective anticancer activity — higher toxicity against tumor cell lines than normal cells, potentially because it targets negatively charged glycosaminoglycans on tumor cell surfaces. The peptide showed no toxicity to host cells and demonstrated strong thermal and protease stability in serum, suggesting practical durability.
Key Numbers
42-mer chimeric peptide · Active against human, avian, and plant pathogens · Antiviral vs HCV, influenza, rotavirus · Selective tumor cell toxicity · No host cell toxicity · Serum-stable
How They Did This
Review of the research team's own multi-year body of work on cLF36, including in vitro antimicrobial testing, computational and in vitro antiviral assessments, cancer cell line studies, chicken feeding trials, and expression in prokaryotic (P170, pET) and eukaryotic (HEK293) systems.
Why This Research Matters
Antibiotic resistance is driving urgent demand for new antimicrobial approaches. cLF36 is interesting because it's derived from camel milk lactoferrin — an immune protein — and engineered to combine two active regions into a single more potent peptide. Its triple-threat activity (antibacterial, antiviral, anticancer) plus favorable safety and stability profile make it a promising candidate, though it remains in early research stages.
The Bigger Picture
Lactoferrin-derived peptides are part of a growing effort to develop antimicrobial alternatives to traditional antibiotics. What makes cLF36 unusual is its triple functionality — antibacterial, antiviral, and anticancer — from a single engineered peptide. If the pharmacokinetic and cost challenges can be solved, chimeric peptides like this could become versatile tools in the post-antibiotic era.
What This Study Doesn't Tell Us
Most evidence is preclinical — in vitro, computational, or animal (chicken) models only. No human trials. Cost-effectiveness unknown. Pharmacokinetic and pharmacodynamic profiles not yet characterized. The review summarizes work primarily from a single research group.
Questions This Raises
- ?Can cLF36 maintain its broad-spectrum activity in human clinical settings, or will physiological conditions reduce its effectiveness?
- ?Is the selective anticancer activity strong enough to be therapeutically useful, or primarily of academic interest?
- ?What production costs and scalability challenges stand between cLF36 and potential clinical development?
Trust & Context
- Key Stat:
- Triple-threat peptide cLF36 demonstrated antibacterial, antiviral, and anticancer activity from a single 42-amino acid chimeric peptide engineered from camel milk lactoferrin
- Evidence Grade:
- This is a preliminary-grade review summarizing largely preclinical evidence — in vitro assays, computational studies, and animal models. No human trials have been conducted. The results are promising but far from clinical application.
- Study Age:
- Published in 2024, this review consolidates several years of research on cLF36 from a single research group, representing the current state of knowledge on this specific peptide.
- Original Title:
- A Review on cLF36, a Novel Recombinant Antimicrobial Peptide-Derived Camel Lactoferrin.
- Published In:
- Probiotics and antimicrobial proteins, 16(5), 1886-1905 (2024)
- Authors:
- Morovati, Solmaz, Baghkheirati, Amir Asghari, Sekhavati, Mohammad Hadi(3), Razmyar, Jamshid
- Database ID:
- RPEP-08902
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is lactoferrin and why is camel lactoferrin special?
Lactoferrin is an immune protein found in milk and other body fluids that helps fight infections. Camel lactoferrin is of particular interest because it has stronger antimicrobial properties than human or bovine versions. The researchers took the most active antimicrobial fragments from camel lactoferrin and combined them into a single, more potent chimeric peptide called cLF36.
How can one peptide fight bacteria, viruses, and cancer?
cLF36 works primarily by interacting with cell membranes. Bacteria, virus-infected cells, and cancer cells all have different surface characteristics than healthy human cells — particularly more negative electrical charges. The peptide appears to exploit these differences, binding to and disrupting pathogen and cancer cell membranes while leaving normal cells alone. This membrane-targeting mechanism is shared by many antimicrobial peptides.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-08902APA
Morovati, Solmaz; Baghkheirati, Amir Asghari; Sekhavati, Mohammad Hadi; Razmyar, Jamshid. (2024). A Review on cLF36, a Novel Recombinant Antimicrobial Peptide-Derived Camel Lactoferrin.. Probiotics and antimicrobial proteins, 16(5), 1886-1905. https://doi.org/10.1007/s12602-024-10285-5
MLA
Morovati, Solmaz, et al. "A Review on cLF36, a Novel Recombinant Antimicrobial Peptide-Derived Camel Lactoferrin.." Probiotics and antimicrobial proteins, 2024. https://doi.org/10.1007/s12602-024-10285-5
RethinkPeptides
RethinkPeptides Research Database. "A Review on cLF36, a Novel Recombinant Antimicrobial Peptide..." RPEP-08902. Retrieved from https://rethinkpeptides.com/research/morovati-2024-a-review-on-clf36
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.